Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for Radiation-Induced Brain Injury
NCT04152681Phase 2Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Oct 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in Radiation-Induced Brain Injury (RIBI), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Overall efficacy rate at 4 weeks. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
Radiation-Induced Brain Injury (RIBI)
Beyond the preview
Go deeper on NCT04152681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152681.